Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

St John's wort, depression, and catecholamines

Christine A Haller1

  • 1University of California, San Francisco, CA 94143, USA. dchaller@worldnet.att.net

Clinical Pharmacology and Therapeutics
|November 13, 2004
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.

Regulatory toxicology and pharmacology : RTP·2010
Same author

Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening.

American journal of epidemiology·2009
Same author

Human pharmacology of a performance-enhancing dietary supplement under resting and exercise conditions.

British journal of clinical pharmacology·2008
Same author

Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites.

Journal of analytical toxicology·2006
Same author

Gamma-hydroxybutyrate and ethanol effects and interactions in humans.

Journal of clinical psychopharmacology·2006
Same author

Clinical approach to adverse events and interactions related to herbal and dietary supplements.

Clinical toxicology (Philadelphia, Pa.)·2006
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
See all related articles